{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974035",
  "id": "02974035",
  "pages": 12,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1741",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8ln6h4687z3.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Quarterly Report (Appendix 4C)**  \n- **Cash balance (30 June 2025):** $5.121 million (down from $5.440 million in Q3 FY25).  \n- **Key operational highlights:**  \n  - **Record quarterly dose sales** (+20% QoQ, +42% YoY; 66% revenue uplift FY25 vs. FY24).  \n  - **G-BA (Germany) tender initiated** for clinical study to support reimbursement pathway.  \n  - **OncoSil\u2122 outperformed SBRT in real-world study**: 22-month median survival vs. 14 months (p=0.004); 22% resection rate vs. 0% for SBRT.  \n  - **Distribution agreement signed** with Pro-Gem for Slovenia.  \n\n#### **Capital Raising**  \n- **Structure:** Placement + Share Purchase Plan (SPP).  \n- **Total raised:** $8.7 million AUD ($3.247 million received in Q4; $5.453 million post-quarter).  \n- **SPP oversubscribed:** $4.5 million applications vs. $2.0 million target.  \n- **Use of funds:** Clinical trials, working capital; extends runway to H2 CY26.  \n\n#### **Corporate Action**  \n- **Capital consolidation completed:** 1-for-400 share consolidation.  \n\n#### **Clinical Trials Update**  \n- **PANCOSIL study (CT-guided delivery):** Recruitment completed (20 patients); data expected late 2025.  \n- **TRIPP-FFX study (FOLFIRINOX combo):** Recruitment completed (88 patients); data expected early 2026.  \n\n---  \n**Omitted:** Director quotes, forward-looking statements, routine administrative details.",
  "usage": {
    "prompt_tokens": 7467,
    "completion_tokens": 377,
    "total_tokens": 7844,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T08:04:38.749419"
}